ClinicalTrials.gg
CompletedNCT02382276Updated Jul 20, 2020Results posted

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

A Phase 3 interventional study of Nalmefene hydrochloride in Alcohol Dependence, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-07-20.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
5th of 12
405 · median 212
Started
2015
with 3 others
Phase 3
6 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
3 of 12
Otsuka Pharmaceutical Co., Ltd.

Among the 12 studies testing nalmefene in Alcoholism, this one is the 5th largest by enrollment, is one of 4 that started in 2015, is one of 6 in phase 3, and was the 7th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.

03

Conditions studied

  • Alcohol Dependence

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have completed Study 339-14-001
  • Patients who have signed the form for Study 339-14-002

Exclusion criteria

Exclusion Criteria:

  • The patient has a unstable illness (eg, complication of (NYHA) class III or IV heart failure or angina pectoris, renal function disorder with estimated (eGFR) of \< 30 mL/min/1.73 m2, hepatic failure, and neoplastic disorder)
  • The patient has a clinically significant abnormal (ECG) which is inappropriate for the participation in the trial in the opinion of the investigator or subinvestigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Nalmefene hydrochloride 20 mg

    As-needed; tablets, orally

    Drug: Nalmefene hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: 24-week treatment period

Secondary outcomes

  1. Change in the Number of Heavy Drinking Days (HDDs) From Baseline

    Time frame: Week 24

  2. Change in Total Alcohol Consumption (TAC) From Baseline

    Time frame: Week 24

07

Results

Posted Jul 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneNalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in Study
Started13794172
Completed12684133
Not completed111039
Withdrew: Withdrawal by subject485
Withdrew: Adverse event7232
Withdrew: Physician decision002

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
24-week treatment period
Reported as:
Number · Number of participants
Number of Participants With Adverse Events
Number of participantsNalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in Study
Number of Participants With Adverse Events9667141
SecondaryChange in the Number of Heavy Drinking Days (HDDs) From Baseline
Time frame:
Week 24
Reported as:
Least squares mean · days/month
Change in the Number of Heavy Drinking Days (HDDs) From Baseline
days/monthNalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in Study
Change in the Number of Heavy Drinking Days (HDDs) From Baseline-15.09 ± 0.77-17.15 ± 0.94-16.35 ± 0.70
SecondaryChange in Total Alcohol Consumption (TAC) From Baseline
Time frame:
Week 24
Reported as:
Least squares mean · g/day
Change in Total Alcohol Consumption (TAC) From Baseline
g/dayNalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in Study
Change in Total Alcohol Consumption (TAC) From Baseline-53.20 ± 2.29-57.93 ± 2.77-55.77 ± 2.06

Adverse events

Collected over 24-week treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total0/403 (0%)3/403 (0.7%)209/403 (51.9%)
Most frequent serious events
Most frequent serious events
EventTotal
GastroenteritisInfections and infestations1/403
DehydrationMetabolism and nutrition disorders1/403
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/403
Most frequent other events
Most frequent other events
EventTotal
NauseaGastrointestinal disorders79/403
NasopharyngitisInfections and infestations62/403
DizzinessNervous system disorders39/403
HeadacheNervous system disorders29/403
MalaiseGeneral disorders26/403
SomnolenceNervous system disorders26/403
VomitingGastrointestinal disorders25/403
Abdominal discomfortGastrointestinal disorders23/403
InsomniaPsychiatric disorders20/403

Baseline characteristics

Safety analysis set, which included all patients who received at least one dose of study medication during the 24-week treatment period in the extension study.

Age, Categorical
Age, Categorical(Participants)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
<=18 years0000
Between 18 and 65 years12085154359
>=65 years1791844
Age, Customized
Age, Customized(years)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Mean50.0 ± 11.750.1 ± 11.048.5 ± 11.049.4 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Female331964116
Male10475108287
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Japanese13794172403
Region of Enrollment
Region of Enrollment(Participants)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Japan13794172403
Heavy Drinking Days (HDDs)
Heavy Drinking Days (HDDs)(days/month)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Mean22.54 ± 6.7024.38 ± 5.1022.70 ± 6.5423.04 ± 6.32
Total Alcohol Consumption (TAC)
Total Alcohol Consumption (TAC)(g/day)Nalmefene 20 mg in the lead-in StudyNalmefene 10 mg in the lead-in StudyPlacebo in the lead-in StudyTotal
Mean94.10 ± 34.4394.16 ± 32.6092.30 ± 41.0393.35 ± 36.90
08

Study locations

7 sites
  • Chubu
    Region, Japan
  • Hokkaido
    Region, Japan
  • Kanto
    Region, Japan
  • Kinki
    Region, Japan
  • Kyusyu
    Region, Japan
  • Tohoku
    Region, Japan
  • Tyugoku
    Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jan 2017, 18 months.

Results were first posted in Jul 2020, 3 years 6 months after primary completion.

Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2015
First posted
Mar 6, 2015
StartActual
Jul 13, 2015
Primary completionActual
Jan 18, 2017
CompletionActual
Jan 18, 2017
Results first posted
Jul 20, 2020
Last update
Jul 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02382276
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 6, 2015
Start date
Jul 13, 2015
Primary completion
Jan 18, 2017
Completion
Jan 18, 2017
Results posted
Jul 20, 2020
Last update
Jul 20, 2020

Study contacts

Ono Hiroaki, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion